Insulet (PODD) Cash & Equivalents Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.16% |
| Dec 31, 2025 | -4.62% |
| Sep 30, 2025 | -2.00% |
| Jun 30, 2025 | 7.56% |
| Mar 31, 2025 | 44.82% |
| Dec 31, 2024 | 34.86% |
| Sep 30, 2024 | 16.54% |
| Jun 30, 2024 | 46.94% |
| Mar 31, 2024 | 42.19% |
| Dec 31, 2023 | 43.96% |
| Sep 30, 2023 | 40.19% |
| Jun 30, 2023 | 37.11% |
| Mar 31, 2023 | 25.03% |
| Dec 31, 2022 | 19.87% |
| Sep 30, 2022 | 47.84% |
| Jun 30, 2022 | 57.34% |
| Mar 31, 2022 | 56.31% |
| Dec 31, 2021 | 41.99% |
| Sep 30, 2021 | 31.80% |
| Jun 30, 2021 | 62.40% |
| Mar 31, 2021 | 49.03% |
| Dec 31, 2020 | 49.21% |
| Sep 30, 2020 | 41.94% |
| Jun 30, 2020 | 39.95% |
| Mar 31, 2020 | 6.70% |
| Dec 31, 2019 | 7.17% |
| Sep 30, 2019 | 23.46% |
| Jun 30, 2019 | -7.35% |
| Mar 31, 2019 | -2.46% |
| Dec 31, 2018 | -5.32% |
| Sep 30, 2018 | -3.84% |
| Jun 30, 2018 | -2.03% |
| Mar 31, 2018 | 6.53% |
| Dec 31, 2017 | 36.61% |
| Sep 30, 2017 | 10.01% |
| Jun 30, 2017 | 0.94% |
| Mar 31, 2017 | -1.74% |
| Dec 31, 2016 | 7.86% |
| Sep 30, 2016 | 15.72% |
| Jun 30, 2016 | -6.65% |
| Mar 31, 2016 | 1.33% |
| Dec 31, 2015 | 1.61% |
| Sep 30, 2015 | 6.96% |
| Jun 30, 2015 | 4.21% |